Peptide RX

back to claim graph

proof receipt / target

TERT

Telomerase reverse transcriptase

grade B status longevity receipt 5984c2c72b6a proof 33%

what this node claims

TERT

Telomerase reverse transcriptase

Open source surface

vertical proof spine

  1. 01 TERT target / grade B / 70% 1 debt
  2. 02 TERT WT fold / grade B / 64% 2 debt

evidence / risk instrument

44%
thin proof
structure evidence gates risk export lineage 44
low debt pressure 21%
28%structuredebt
pLDDT pending
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine

proof completeness

33% missing alphafold_metric, candidate, finding, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

binding partners
    context annotations
    0
    family
    reverse_transcriptase
    functional sites
      gene symbol
      TERT
      go terms
        uniprot
        O14746

        AlphaFold metrics visual

        Confident backbone model

        80.2

        1132 residues / min 21.31 / max 98.56 / source alphafold db

        PAE matrix for linked target
        Very high 58.3% 660 residues / >=90
        Confident 21.1% 239 residues / 70-89
        Low 3.9% 44 residues / 50-69
        Very low 16.7% 189 residues / <50

        usable fold context with explicit model-confidence limits

        Near-complete coverage / observed 1132 of 1132 residues.

        • residues 179-323 / mean 28.06
        • residues 417-443 / mean 38.37
        • residues 636-654 / mean 47.04
        • residues 367-380 / mean 46.25
        proof debt register

        Visible limits, not hidden cleanup.

        21%

        Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

        medium missing functional-site annotations link target annotation, GO term, or binding-site context
        low computational-only status add independent evidence, challenge result, or witness review before strengthening
        medium no candidate yet leave visible until a stronger public receipt resolves it

        weakness and challenge edges

        What would stop this from becoming stronger.

        debt severity export claim strength next proof needed
        missing functional-site annotations medium visible weakens link target annotation, GO term, or binding-site context
        computational-only status low visible watch add independent evidence, challenge result, or witness review before strengthening
        no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it

        what supports it

        No upstream proof edge yet.

        what it supports

        target has structure prediction target:dcba88f5-3271-41fb-9e87-60505135534d -> fold:e7169022-fda3-45ba-a266-850753926013 folds_to / B / 0.802

        Research-use boundary

        This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.